For example, certain clinical trials using primary T cells with TCR- and/or HLA-knockout are known to diminish the alloreactivity of T cells32,33, whereas PD-1- or CTLA-4 knockout can overcome immunosuppression of the tumour microenvironment34,35. Here, PDCD1 is linked to neoplasm.